Edesa Biotech Inc

CEO’s fresh insider buy of Edesa Biotech shares shows confidence in upcoming clinical milestones, hinting at a potential upside for long‑term investors.

CEO Pardeep Nijhawan’s steady buying at low prices shows Edesa Biotech’s strong outlook—boosted by 516% monthly earnings, 58% weekly gains and a disciplined 10k‑share strategy. Investors may spot upside before the stock hits new highs.

CEO’s recent 10,000‑share buy at $3.26 signals confidence for Edesa Biotech, yet investors must weigh weak earnings, clinical milestones, and potential dilution.

Insider buying boosts optimism for Edesa Biotech—CEO’s latest 10k-share purchase signals confidence ahead of key clinical milestones.

CEO Nijhawan Pardeep’s recent bulk buy of Edesa Biotech shares at $2 each signals bullish confidence amid a 337% rally, suggesting optimism for upcoming clinical milestones.

CEO Nijhawan Pardeep’s recent bulk buying of Edesa Biotech shares signals insider confidence, hinting at potential upside as the company advances its clinical pipeline.